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To the Editor: 
Throughout the last decade, thousands of refugees arrived on a daily basis on the 
Mediterranean coast of Southern-European countries. As this influx is not expected to slow 
down, developing national and European strategies is required to ensure appropriate and 
accessible health care to these vulnerable populations.1,2 The vast majority of these 
migrants come from areas in which sickle cell disease (SCD) and other 
hemoglobinopathies are highly prevalent. Limited data are available on the burden of 
these disorders in populations of refugees. Here, we present two pieces of evidence 
supporting the need for specific strategies for the early identification of SCD in refugees. 
First, we carried out a retrospective study of data collected during the period 2014-2017 
across 13 Italian reference centers for SCD and hemoglobinopathies. The primary 
outcome of this study was to identify events associated with the new diagnosis of SCD in 
refugees and the secondary outcome was to evaluate the impact of hemoglobinopathies in 
refugees coming from endemic areas. The descriptive analysis of variables was performed 
with counts, percentages, mean and standard deviation (SD) or median and interquartile 
range (IQR: 25th - 75th percentile). Then, we discuss the results of a pilot study which 
screened all refugees seen in a single second-level refugee center during October 2017, 
using one of the new rapid point of care screening devices (SickleSCAN® BioMedomics, 
inc.). The aim was to fast-track the care of individuals with SCD and the collection of 
relevant demographic data.3-5 The results were then validated by HPLC, the standard gold-
standard screening method.3-5   
Based on data from the Italian Ministry of Interior, a total of 624,688 refugees 
landed on the Italian coast between 2014 and 2017 (Fig. 1A).6 Refugees from Syria only 
represented 4-25% of these each year (Fig. 1A, B), while 21-53% came from sub-Saharan 
African countries (21% in 2014, 31% in 2015, 53% in 2016 and 46% in 2017). Refugees 
generally disembark on known hotspots on the coast of Southern Italy. They are then 
relocated in second-level reception centers throughout the country, before being screened 
for communicable diseases and undergoing the vaccination program recommended by the 
World Health Organization (WHO) within two weeks after their arrival. Screening for non-
communicable disorders (NCD) such as SCD is not conducted. SCD is a common red cell 
disorder identified as a global health priority by the African-Union and WHO.7,8 Life-
threatening complications of SCD include acute vaso-occlusive painful events, acute chest 
syndrome and splenic sequestration, which require early identification and intensive 
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clinical management. In addition, dehydration, psychologic stress, and exposure to 
high/low temperature can trigger vaso-occlusive events in patients with SCD. Refugees 
represent marginalized and vulnerable people, exposed to extreme conditions during their 
travels, mostly through Africa, to the coast of Southern European countries. The delay in 
the identification of SCD may lead to severe acute organ complications and fatal 
outcomes.9,10 To help managing acute health problems related to SCD which might 
dominate the first phase of transition of refugees, we have developed an algorithm for the 
management of acute events in emergency department (ED) and we promoted specific 
knowledge of SCD, with training sessions and seminars dedicated to physicians of the 
EDs, pediatricians, hematologists and internal medicine physicians.10  
Our retrospective study shows that SCD is relatively common in refugees accessing 
ED for acute sickle cell related events. Over the four years studied, we identified 70 
patients with hemoglobinopathies, with 50% of adults (86% male, 14% female, median age 
21 years, IQR 18.5-19 years) and 50% of children (80% male, 20% female, median age 10 
years, IQR 1-16 years). The counts of refugees and patients with SCD as a function of 
their origin revealed a peak of SCD identification in 2016 (respectively 17%, 17%, 48% 
and 17%), corresponding to the arrival of a large number of refugees from Sub-Saharan 
Africa (respectively 15%, 20%, 41%, 24%) (Fig. 1B).The overall genotypic distribution was 
as follow: SS (n=49), SC (n=9), Sβ-thalassemia (Sβ, n=3), CC (n=2), AS (n=1) and 
transfusion dependent β-thalassemia (TDT, n=6). The analysis of genotypes combined 
with patient origin revealed that 61.4% of the SS individuals identified were from sub-
Saharan Africa (Fig. 1C). SC patients were mainly from West African countries, whereas, 
TDT patients were from Syria (7.1 %) and Bangladesh (1.4 %) (Fig. 1C). As shown in Fig. 
2A, acute events were mainly responsible for the identification of SCD in refugees. The 
main reasons for access to ED of previously undiagnosed SCD were qualitatively similar to 
those seen in the native Italian SCD population11 or other SCD groups, 12,13 except for 
anemia, which appeared to be the second main cause of access to ED in our study 
population. Although we did not have access to historical patient hematologic data, we 
cannot exclude the possible contribution of malnutrition to anemia in refugees with SCD. 
Amongst the individuals with SCD for which hemoglobin (Hb) data were recorded (n=46), 
13% had Hb levels were <8 g/dL and 83% Hb levels were > 8 g/dL. Although we have not 
access to historical patient hematologic data, we cannot exclude the possible contribution 
of malnutrition to anemia in refugees with SCD. This is consistent with a recent report of 
data from German refugee centers, where anemia was recognized in 22.5% of the 
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refugees.14 82.9% of patients were diagnosed with SCD within the first 11 months after 
their arrival in Italy, and 14.3 % during the second year. In a small group of refugees 
(n=14), SCD was also identified outside acute events and the main causes are 
summarized in Fig. 2A. Among these, 2.9 % were identified through early pregnancy 
counseling or through the management of complications in pregnancy related to (i) severe 
clinical manifestations due to SCD (venous cerebral thrombosis 1.4%); or (ii) obstetrical 
complications (spontaneous abortion, 1.4%).15 Collectively, our results indicate the need of 
screening for SCD in refugees at their arrival in order to prevent severe acute and life-
threatening clinical manifestations. This is also supported by a document from the Division 
of Global Migration and Quarantine of the United State Department of Health and Human 
Service (2016)16 and by the introduction of SCD screening by Canadian health authorities, 
due to the increasing prevalence of SCD related to migration fluxes in North America.17 
Indeed, data on our prospective study that screened all asymptomatic refugees in one 
second-level refugee center identified 3% SCD patients and 20% AS individuals over 400 
screened individuals. The analysis of genotypes combined with data on patients’ origins 
revealed that 2.6% of SCD patients were from sub-Saharan Africa. HbS carriers were from 
Nigeria (11.5%), Guinea (2.6%), Ivory Coast (2.1%), Senegal (1.6%) and the 0.5% from 
Burkina Faso, Gambia, Ghana and Guinea Bissau respectively; HbC carriers were from 
Ivory Coast (1%), Ghana (1%), Guinea (1%), Mali (0.5%) and Nigeria (0.5%); HbD carriers 
were from Nigeria (0.5%) and the β−thalassemia carriers were from Gambia (0.5%) and 
Guinea (0.5%). 71.4% of the individuals screened did not have any hemoglobinopathy. 
None of the newly identified SCD patients was aware of their condition.  
Since SCD and β-thalassemia are endemic in several parts of Italy, a national 
network of refence centers has been established in the last five decades for the clinical 
management of these patients, ensuring pre-conception counseling and pre-natal 
diagnosis.18 In addition, this network allowed to identify the ongoing epidemiological 
change across the country.11,19-21 This makes the Italian experience unique compared to 
other European countries with a lower incidence of SCD. In our study, refugees with SCD 
were all re-directed to the comprehensive SCD centers of the area. 60% of them were 
taken in charge within the first 11 months from their first access to an ED and 32.9 % 
within the second year. Patients with SCD were then placed under hydroxyurea treatment 
and followed-up by the comprehensive SCD centers of the area. A multidisciplinary 
working group on health care in refugees is now analyzing the possibility of introducing 
routine screening of SCD as NCD in refugees. 
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In conclusion, our data support the recommendation that SCD should be screened 
in refugees coming from endemic areas for SCD. To appropriately address this problem 
and to face the current situation of dynamic changes in the distribution and prevalence of 
SCD in European countries, we propose (i) to develop flow-charts facilitating the early and 
systematic identification of SCD in refugees at their arrival or in second level refugee 
camps; (ii) to educate health professionals such as ED physicians, pediatricians, internal 
medicine doctors and hematologists in the early identification and treatment of acute vaso-
occlusive events; (iii) to rapidly refer SCD or symptomatic HbS-carrier refugees to the 
comprehensive-SCD-reference center for treatment and follow-up and (iv) to rapidly start 
disease modifying treatment such as HU. These actions will allow for an earlier 
identification of patients with SCD, preventing severe complications and decreasing the 
overall healthcare costs associated with this population.   
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FIGURE LEGENDS 
Fig 1. (A) Counts of total refugees in Italy, of refugees from Sub-Saharan area and from 
Syria in the period between 2014 and 2017. (B) Map showing the fluxes of refugees 
identified with hemoglobinopathies (sickle cell disease or transfusion dependent 
thalassemia-TDT) after their arrival in Italy between 2014 and 2017. Countries of origin are 
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shown in dark grey. The country of destination, Italy, is shown in dark red. (C) Counts of 
patients with hemoglobinopathies (sickle cell disease or transfusion dependent 
thalassemia-TDT), differentiated by genotype, as a function of the nationality.  
Fig 2. (A) Type and frequency of acute and non-acute events identified in refugees 
identified with a hemoglobinopathies in Italy between 2014 and 2017. * Other include: 
cardiopathy (n=1), seizures (n=1), splenic infarction and thrombosis of central retinal vein 
(n=1), left gonalgia in severe gonarthrosis and joint deformities in septic arthritis outcomes 
(n=1), inconsolable crying of a baby (n=1) and genetic counselling for the second 
pregnancy of a mother (n=1). (B) Percentage of patients screened, in a second level 
refugee center with the new point of care screening device as a way of fast-tracking the 
individuals with SCD, differentiated by genotype, as a function of the nationality.  
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